SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS

被引：32

作者：

Zaoutis, Theoklis ^{[1
,2
,3
]}

Lehrnbecher, Thomas ^{[4
]}

Groll, Andreas H. ^{[5
]}

Steinbach, William J. ^{[6
,7
]}

Jafri, Hasan S. ^{[8
]}

Maertens, Johan ^{[9
]}

Ngai, Angela L. ^{[10
,11
,12
]}

Chow, Joseph W. ^{[10
,11
,12
]}

Taylor, Arlene F. ^{[10
,11
,12
]}

Strohmaier, Kim M. ^{[10
,11
,12
]}

Bourque, Michael ^{[10
,11
,12
]}

Bradshaw, Susan K. ^{[10
,11
,12
]}

Petrecz, Maria ^{[10
,11
,12
]}

Kartsonis, Nicholas A. ^{[10
,11
,12
]}

机构：

[1] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA

[2] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA

[3] Univ Penn, Sch Med, Dept Pediat & Epidemiol, Philadelphia, PA 19104 USA

[4] Goethe Univ Frankfurt, Frankfurt, Germany

[5] Univ Childrens Hosp Muenster, Munster, Germany

[6] Duke Univ, Dept Pediat, Div Pediat Infect Dis, Durham, NC 27706 USA

[7] Duke Univ, Dept Mol Genet & Microbiol, Div Pediat Infect Dis, Durham, NC USA

[8] Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Pediat Infect Dis, Dallas, TX 75390 USA

[9] Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Leuven, Belgium

[10] Merck Res Labs, Dept Clin Res, West Point, PA USA

[11] Merck Res Labs, Dept Biostat, West Point, PA USA

[12] Merck Res Labs, Dept Med Commun, West Point, PA USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2009年 / 28卷 / 12期

关键词：

caspofungin; safety; invasive mycoses; empirical therapy; pediatric patients; AMPHOTERICIN-B;

D O I：

10.1097/INF.0b013e3181af5a15

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, I week to 17 years of age. Caspofungin was administered for I to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.

引用

页码：1132 / 1135

页数：4

共 11 条

[1] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis [J].

Abruzzo, GK ;

Flattery, AM ;

Gill, CJ ;

Kong, L ;

Smith, JG ;

Pikounis, VB ;

Balkovec, JM ;

Bouffard, AF ;

Dropinski, JF ;

Rosen, H ;

Kropp, H ;

Bartizal, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2333-2338

[2] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[3]

MAERTENS J, 2007, 47 INT C ANT AG CHEM

[4]

*MERCK CO INC, 2008, CANCIDAS CASP AC INJ

[5] Comparison of caspofungin and amphotericin B for invasive candidiasis. [J].

Mora-Duarte, J ;

Betts, R ;

Rotstein, C ;

Colombo, AL ;

Thompson-Moya, L ;

Smietana, J ;

Lupinacci, R ;

Sable, C ;

Kartsonis, N ;

Perfect, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2020-2029

[6] Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers [J].

Neely, Michael ;

Jafri, Hasan S. ;

Seibel, Nita ;

Knapp, Katherine ;

Adamson, Peter C. ;

Bradshaw, Susan K. ;

Strohmaier, Kim M. ;

Sun, Peng ;

Bi, Sheng ;

Dockendorf, Marissa Fallon ;

Stone, Julie A. ;

Kartsonis, Nicholas A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (04) :1450-1456

[7]

Sable C A, 2002, Transpl Infect Dis, V4, P25, DOI 10.1034/j.1399-3062.2002.01004.x

[8] Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age [J].

Saez-Llorens, Xavier ;

Macias, Mercedes ;

Maiya, Padmanabha ;

Pineros, Juan ;

Jafri, Hasan S. ;

Chatterjee, Archana ;

Ruiz, Gloria ;

Raghavan, Janaki ;

Bradshaw, Susan K. ;

Kartsonis, Nicholas A. ;

Sun, Peng ;

Strohmaier, Kim M. ;

Fallon, Marissa ;

Bi, Sheng ;

Stone, Julie A. ;

Chow, Joseph W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :869-875

[9] Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents [J].

Walsh, TJ ;

Adamson, PC ;

Seibel, NL ;

Flynn, PM ;

Neely, MN ;

Schwartz, C ;

Shad, A ;

Kaplan, SL ;

Roden, MM ;

Stone, JA ;

Miller, A ;

Bradshaw, SK ;

Li, SX ;

Sable, CA ;

Kartsonis, NA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4536-4545

[10] Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia [J].

Walsh, TJ ;

Teppler, H ;

Donowitz, GR ;

Maertens, JA ;

Baden, LR ;

Dmoszynska, A ;

Cornely, OA ;

Bourque, MR ;

Lupinacci, RJ ;

Sable, CA ;

dePauw, BE .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) :1391-1402

← 1 2 →